Two isoforms, alpha and beta, make up the multifunctional serine/threonine kinase known as glycogen synthase kinase-3 (GSK-3). It controls the receptor tyrosine kinase, cytokine, and Wnt signaling pathways negatively and is highly conserved. Inhibiting GSK-3 through the stimulation of these pathways affects a variety of downstream effectors, such as transcription factors, nutrient sensors, glycogen synthesis, mitochondrial function, circadian rhythm, and cell fate. In response to T-cell receptor activation, GSK-3 also controls alternative splicing, and current phosphoproteomic studies have shown that numerous splicing regulators and splicing factors are phosphorylated in a GSK-3-dependent manner.
Alzheimer's disease (AD) and other neurodegenerative pathologies, as well as other types of diseases like diabetes, cardiovascular problems, and cancer, are caused by the dysfunction or abnormal activity of GSK-3. GSK-3 is a prime candidate for therapeutic intervention because it is also connected to innate immune defense against pathogens.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69839 | (E/Z)-GSK-3β inhibitor 1 | 3367-88-2 | (E/Z)-GSK-3β inhibitor 1 is the racemate of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1. |
|
V69853 | (R)-BRD3731 | 2056262-08-7 | (R)-BRD3731 is a GSK3 inhibitor (antagonist) with IC50s of 1.05 and 6.7 μM for GSK3β and GSK3α, respectively. |
|
V0224 | 1-Azakenpaullone (1-Akp) | 676596-65-9 | 1-Azakenpaullone(1-Akp), an analog of kenpaullone, is a novel, ATP-competitive and selective inhibitor of GSK-3β (glycogen synthase kinase 3β) with potentialantidiabetic and neuroprotective activities. |
|
V69852 | 2B-(SP) | 186901-17-7 | 2B-(SP) is an eIF2B-based glycogen synthase kinase-3 (GSK-3) substrate. |
|
V77571 | 2B-(SP) (TFA) | 2B-(SP) TFA is an eIF2B-based glycogen synthase kinase-3 (GSK-3) substrate. | |
|
V69845 | 6-Me-ATP (N6-Methyl-ATP) | 3130-39-0 | 6-Me-ATP (N6-Methyl-ATP) is an N6-modified ATP analogue. |
|
V77676 | 6-Me-ATP trisodium (N6-Methyl-ATP trisodium) | 6-Me-ATP (N6-Methyl-ATP) trisodium is an N6-modified ATP analogue. | |
|
V0228 | BIO-acetoxime (GSK-3 Inhibitor X; BIA) | 667463-85-6 | BIO-acetoxime (also known asGSK-3 Inhibitor X;BIA),a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, is a novel, potent and selective dual inhibitor of GSK3α/β (glycogen synthase kinase-3) with potentialanti-infection andanticonvulsant as well as anticancereffects. |
|
V9740 | 9-ING-41 | 1034895-42-5 | 9-ING-41 is a glycogen synthase kinase-3 (GSK-3) inhibitor that induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. |
|
V69859 | AChE/BACE1/GSK3β-IN-1 | 2866066-81-9 | AChE/BACE1/GSK3β-IN-1 is an orally bioactive triple inhibitor of AChE/BACE1/GSK3β. |
|
V0220 | AZD1080 | 612487-72-6 | AZD1080 is a selective, potent,orally bioactive, and brain permeable GSK3 (glycogen synthase kinase-3) inhibitor with neuroprotective effects. |
|
V0219 | AZD2858 | 486424-20-8 | AZD2858 is a novel, potent, orally bioactive, and selective GSK-3 (glycogen synthase kinase-3) inhibitor with the potential to be used in fracture healing. |
|
V37593 | BRD0705 | 2056261-41-5 | BRD0705 is a novel, potent,paralog selectiveand orally bioactive glycogen synthase kinase 3α (GSK3α) inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. |
|
V69851 | BRD3731 | 2056262-07-6 | BRD3731 is a selective GSK3β inhibitor (antagonist) with IC50s of 15 nM and 215 nM for GSK3β and GSK3α respectively. |
|
V4053 | BRD5648 | 2056261-42-6 | BRD-5648 (also known as (R)-BRD-0705) is an inactive (R)-enantiomer of BRD-0705. |
|
V87894 | CDK5-IN-4 | 1212711-91-5 | CDK5-IN-4 (compound 4) is a potent multikinase type II inhibitor targeting CDK5 with IC50 of 9.8 μM. |
|
V78317 | CDK7-IN-20 | 3034210-97-1 | CDK7-IN-20 is a specific, irreversible inhibitor of CDK7 (CDK) with IC50 of 4 nM. |
|
V0213 | CHIR-98014 | 252935-94-7 | CHIR-98014 (also known as CT-98024) is a novel, potent, reversible, cell-permeable inhibitor of GSK-3 (glycogen synthase kinase-3) with potential anti-diabetic activity. |
|
V87893 | COB-187 | 1862177-86-3 | COB-187 is a potent, ATP-competitive, and selective GSK-3β inhibitor. |
|
V3199 | CP21R7 | 125314-13-8 | CP21R7 (also known CP21) is a potent and highly selectiveGSK-3βinhibitor that can potently activate canonical Wnt signalling with IC(50) of 0.6nM for GSK-3β. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
